IMDELLTRA ( TARLATAMAB By AMGEN ) Aprobado Por la USFDA Para Tratar Pacientes con Cáncer de Pulmón de Células Pequeñas Que Han Empeorado Durante o Después del Tratamiento con Quimioterapia Basada en PLATINO .

 

IMDELLTRA Is USFDA Approved to Treat EXTENSIVE STAGE SMALL CELL LUNG CÁNCER in Adults in Certain Situations . ( “ Extensive ” Means The Cáncer Has Spread Through The Lungs, To Nearby Lymph Nodes, Or To Other Parts Of The Body ) .

For This Use, The Cáncer must have Worsened During Or After Treatment With Platinum-Based Chemotherapy .

IMDELLTRA Contains The Active Ingredient TARLATAMAB - DLLE And Is a Type Of IMMUNOTHERAPY 

 DRUG DETAILS 

Here Is Key Information About IMDELLTRA :

• Drug Class : Bispecific DLL3-Directed CD3 T-Cell Engager, Which Is a Type Of Immunotherapy .

• Drug Form : Powder That Is Mixed With Liquid To Form a Solution For Intravenous (IV) Infusion .

• Generic Or Biosimilar Available ? : No .

• Prescription Required ? : Yes .

• Controlled Substance ? : No .

• Year of FDA APPROVAL : 2024 .

• Accelerated APPROVAL ? : Yes . ...